First Patient Dosed with new Formulation of AO-252

Only one patient dosed so far; all progress claims are projections, not results.

What the company is saying

Coiled Therapeutics plc announces the dosing of the first patient in the United States with its new lipid-based oral formulation of AO-252. The company frames this as a milestone towards larger dose-expansion cohorts in ovarian and prostate cancer, targeting up to 30 patients by Q4 2026. Prior clinical benefit rates of 80% (BID) and 40% (QD) are highlighted, but these figures come from the earlier tablet formulation and very small cohorts (n=5 each). The announcement emphasizes improved absorption and potential for higher dosing with the new formulation, but provides no supporting pharmacokinetic or safety data. Commercial interest from large pharmaceutical companies is referenced, but no evidence or specifics are disclosed. The tone is optimistic and forward-looking, with most claims about future plans rather than realised achievements.

What the data suggests

The only realised milestone is the dosing of a single patient with the new AO-252 formulation in the United States. All efficacy data cited—80% clinical benefit rate for BID dosing and 40% for QD—comes from the previous tablet formulation, each based on just five patients. No pharmacokinetic, safety, or efficacy data for the new formulation are disclosed. There are no financial figures, cash balances, or funding details provided. The company projects enrolling up to 30 patients by Q4 2026 and expects initial safety and pharmacokinetic data in Q4 2026, but these are forward-looking statements. The data quality is limited, with no statistical analysis, no period-over-period comparisons, and no operational or financial metrics to assess progress or risk. The evidence base for the new formulation's benefits is entirely aspirational at this stage.

Analysis

The announcement is upbeat, highlighting the dosing of the first patient with a new formulation and referencing prior small-cohort clinical benefit rates. However, most of the key claims are forward-looking, including expectations for safety/pharmacokinetic data, plans for dose-expansion cohorts, and commercial interest. The only realised milestone is the dosing of a single patient with the new formulation; all efficacy data cited is from the previous tablet formulation and small sample sizes (n=5 per group). There is no disclosure of profitability, revenue, or financial metrics, and no mention of capital outlay or funding. The language inflates the signal by implying imminent progress and commercial traction, but the actual evidence is limited to early-stage clinical activity and plans. The gap between narrative and evidence is moderate: the company is at an early clinical stage, and while the tone is positive, the measurable progress is minimal.

Risk flags

• ●Clinical risk is high: only one patient has received the new formulation, and all efficacy data comes from the previous tablet version with very small sample sizes (n=5 per cohort). This means there is no evidence yet that the new formulation delivers on its claimed benefits.
• ●Disclosure risk is significant: the announcement lacks any financial data, detailed safety results, or pharmacokinetic data for the new formulation. Investors cannot assess capital adequacy, burn rate, or operational runway from the information provided.
• ●Execution risk is material: the company's plans depend on enrolling up to 30 patients and initiating dose-expansion cohorts in H2 2026, but there is no evidence of recruitment progress beyond the first patient. Delays or challenges in patient enrollment could materially impact timelines.
• ●Commercialisation risk is present: references to commercial interest from large pharmaceutical companies are unsubstantiated by any agreements or documented interactions. Without concrete partnership or offtake deals, the pathway to revenue remains speculative.

Bottom line

This announcement signals early-stage clinical progress, but the only concrete achievement is dosing a single patient with the new AO-252 formulation. All efficacy data cited is from the old formulation and very small cohorts, offering little predictive value for broader success. No financial, safety, or pharmacokinetic data for the new formulation are disclosed, leaving investors without the means to assess capital strength or clinical risk. References to commercial interest are unsupported by evidence or agreements. The company's narrative is optimistic but rests almost entirely on projections and planned milestones rather than realised results. For investors, this update is not actionable as a signal of near-term value creation. The most important takeaway is that meaningful clinical or commercial data—and thus any investment case—remains at least a year away, contingent on successful patient enrollment and delivery of credible trial results.

Announcement summary

(AIM: COIL) (OTCQB: COTXF) Coiled Therapeutics plc announced that the first patient in the United States has been dosed with the Company's optimised lipid-based oral formulation of AO-252. The new formulation is designed to provide more consistent, dose-proportional absorption than the previous tablet formulation, which showed dose-dependent absorption limitations. In the ongoing Phase I trial, the twice-daily (BID) dosing cohort using the tablet formulation achieved an 80% Clinical Benefit Rate (n=5) in patients with an average of five prior lines of therapy, compared with 40% in the once-daily dosing cohort (n=5), as previously announced on 7 July 2026. The company is targeting up to 30 patients by Q4 2026 in planned dose-expansion cohorts in ovarian and prostate cancer. Initial post-dose safety monitoring identified no treatment-related adverse safety findings. Coiled Therapeutics expects initial safety and pharmacokinetic data from the new formulation in Q4 2026. The company plans to initiate Phase I/II dose-expansion cohorts in ovarian and prostate cancer in H2 2026.

Disagree with this article?